Tresiba EMA vs FDA: What the Regulatory Difference Means for Women Using Insulin Degludec

Why the FDA and EMA Reached Tresiba at Different Times

The EMA and FDA looked at essentially the same clinical package and reached different conclusions about what extra evidence was needed. The EMA was satisfied with the phase 3 BEGIN trial program by 2013. The FDA was not, at least not on cardiovascular safety.

Under the FDA's 2008 guidance on cardiovascular outcomes for diabetes drugs, any new glucose-lowering agent had to demonstrate that its upper bound of the 95% confidence interval for major adverse cardiovascular events (MACE) stayed below 1.8 before approval, and below 1.3 for full approval without a post-market outcomes trial. Novo Nordisk's initial submission showed a point estimate that was reassuring, but the confidence interval was wide enough to give the agency pause. The FDA issued a Complete Response Letter and required a dedicated cardiovascular outcomes trial before it would approve.

That trial, DEVOTE, randomized 7,637 high-cardiovascular-risk adults with type 2 diabetes to insulin degludec or insulin glargine U-100. The primary endpoint was confirmed nonfatal MI, nonfatal stroke, or cardiovascular death. DEVOTE reported a hazard ratio of 0.91 (95% CI 0.78-1.06), confirming non-inferiority and clearing the <1.3 threshold the FDA needed. The FDA granted approval on September 26, 2015, roughly 26 months after the EMA.

What the EMA Required That the FDA Did Not

The EMA approval came with a specific requirement for post-authorization safety studies through the EU pharmacovigilance system. The European Public Assessment Report (EPAR) for Tresiba required Novo Nordisk to submit annual safety reports and a registry-based study on use in pregnancy, acknowledging that the pre-approval pregnancy dataset was sparse. The FDA's post-market requirements centered on the DEVOTE outcomes data and ongoing Sentinel surveillance, rather than a dedicated pregnancy registry.

This difference matters for you as a woman: the EU pregnancy registry generates real-world data on insulin degludec use across trimesters that is still being collected and published, and it represents a more granular commitment to understanding how this drug behaves during gestation.

The Label Differences You Will Actually Notice

The FDA label and the EMA SmPC (Summary of Product Characteristics) are not identical documents, and several practical differences affect women.

The FDA label specifies that the dose should be administered once daily at any time of day, but that the interval between doses must be at least 8 hours. The EMA SmPC says the same but adds a direct statement that Tresiba can be injected at any time of day, "with flexibility to change the time of injection from day to day if necessary." This flexibility language is slightly more permissive in the European document and has shaped how European diabetes educators counsel shift workers and patients with irregular schedules, including women whose routines shift around menstrual-cycle symptoms, postpartum newborn feeding, or perimenopausal sleep disruption.

The EMA SmPC also provides a more detailed titration table, recommending dose adjustments of 2 units every 3-4 days based on fasting glucose values. The FDA label states "individualize dose" without the same prescriptive table, leaving more to clinical discretion.

The DEVOTE Trial: What It Found and What It Missed for Women

DEVOTE is the foundational cardiovascular safety trial that finally got Tresiba onto the US market. Published in the New England Journal of Medicine in 2017, it enrolled patients with type 2 diabetes who had established cardiovascular disease or high cardiovascular risk. The trial ran for a median of 2.0 years.

Cardiovascular Results

The primary endpoint occurred in 8.5% of the insulin degludec group versus 9.3% of the insulin glargine group (HR 0.91; 95% CI 0.78-1.06), confirming non-inferiority. That result was enough to satisfy the FDA's pre-specified threshold and move the drug to approval.

Hypoglycemia: The Finding That Matters More Day-to-Day

Severe hypoglycemia occurred at a rate 38% lower with insulin degludec than with glargine U-100 in DEVOTE (rate ratio 0.60; 95% CI 0.48-0.76; p<0.001). Nocturnal severe hypoglycemia was 53% lower. These are not minor differences. Hypoglycemia is the event most women with insulin-treated diabetes fear on a practical, daily basis.

What DEVOTE Did Not Study

DEVOTE enrolled patients with high cardiovascular risk, meaning older adults with established disease. The mean age was 65 years. Women represented approximately 37% of the trial population. No pre-specified sex-stratified analysis of cardiovascular outcomes was published in the primary paper, which is a meaningful evidence gap given that women with diabetes carry a proportionally higher relative cardiovascular risk than men with diabetes. Subgroup analyses by sex were reported in supplementary tables and did not show a statistically significant interaction, but the trial was not powered to detect sex differences independently.

This creates a practical clinical framework for women: the hypoglycemia reduction data from DEVOTE applies broadly and is the strongest argument for insulin degludec over glargine U-100 in women who have had nocturnal hypoglycemia. The cardiovascular non-inferiority result should be interpreted with the caveat that women were a minority and no sex-specific cardiovascular claim can be made with confidence.

Sex-Specific Physiology and Dosing Across Life Stages

Insulin requirements in women are not static. They shift with the menstrual cycle, with pregnancy, with the postpartum period, and again through perimenopause and beyond. Because insulin degludec has a flatter pharmacodynamic profile and longer half-life than insulin glargine U-100, it may handle these hormonal swings differently, though head-to-head data in these specific female populations are thin.

Menstrual Cycle and Insulin Sensitivity

Estrogen generally improves insulin sensitivity, while progesterone tends to worsen it. In the luteal phase (days 15-28 of a typical cycle), progesterone rises and many women with type 1 or insulin-requiring type 2 diabetes see fasting glucose climb despite the same basal dose. Because insulin degludec's half-life is approximately 25 hours and it reaches steady state after 2-3 days, mid-cycle dose adjustments require advance planning: a change made on day 14 will not fully reflect in glucose values until around day 17. Women adjusting basal insulin around their cycle need to account for this lag.

PCOS and Insulin Resistance

Women with polycystic ovary syndrome (PCOS) have a high prevalence of insulin resistance even in the absence of formal type 2 diabetes, and many who progress to insulin-requiring diabetes will carry their PCOS-related metabolic phenotype into treatment. In these women, basal insulin requirements may be higher per kilogram of body weight than in women without PCOS. There is no dedicated trial of insulin degludec in PCOS-related diabetes, which is an evidence gap that the registry studies required by the EMA may partially address over time.

Perimenopause and Postmenopause

Estrogen decline during perimenopause and the postmenopausal years worsens insulin resistance and increases visceral adiposity, which can raise basal insulin requirements substantially. Women who were previously stable on a fixed basal dose may find that dose becomes inadequate in their mid-40s without any change in diet or activity. The flexibility of insulin degludec dosing is clinically useful here: perimenopausal women often have erratic sleep, night sweats that mimic nocturnal hypoglycemia symptoms, and variable appetite, all of which are better tolerated with a flatter, longer-acting basal insulin.

The 53% reduction in nocturnal severe hypoglycemia seen in DEVOTE is particularly relevant for this group. Nocturnal hypoglycemia in a woman with hot flashes and disrupted sleep is harder to detect and more dangerous than in a younger woman with intact sleep architecture.

Thyroid and Metabolic Overlap

Women with type 1 diabetes have a threefold higher risk of autoimmune thyroid disease than the general population. Hypothyroidism slows insulin clearance and can cause unpredictable hypoglycemia even on a previously stable basal dose. If you are taking Tresiba and develop unexplained hypoglycemia, thyroid function should be checked before simply reducing the insulin dose.

Pregnancy and Lactation Safety

Tresiba is not recommended as the first-choice basal insulin in pregnancy. This is a direct statement from both ACOG and the FDA label. Neutral protamine Hagedorn (NPH) insulin and insulin detemir have substantially more human pregnancy safety data, and insulin detemir is the only basal analog with a randomized controlled trial in pregnant women (the INSIGHT trial).

What the Human Data Show for Insulin Degludec in Pregnancy

Human data are limited. The pre-approval clinical program excluded pregnant women. The EU pregnancy registry required by the EMA as a post-authorization measure is the primary prospective data source, and results are still maturing. Case series and observational data published through 2024 have not identified a specific teratogenic signal, but the number of exposed pregnancies with complete outcome data remains small.

Animal reproductive studies showed embryo-fetal toxicity at doses approximately 5 times the human therapeutic exposure, including fetal loss and skeletal malformations. These findings do not automatically translate to humans, but they are why the label carries a precautionary statement.

Dose Changes During Pregnancy

If a woman with preexisting diabetes becomes pregnant while on Tresiba and her provider decides to continue it (a case-by-case clinical decision), she should expect insulin requirements to rise dramatically. Total daily insulin requirements typically increase 50-100% between the first and third trimesters as placental hormones drive insulin resistance. Because insulin degludec is dosed once daily, dose titration during pregnancy requires careful monitoring of fasting glucose and overnight glucose trends, ideally with continuous glucose monitoring (CGM).

Gestational Diabetes

Tresiba is generally not used for gestational diabetes (GDM). GDM management follows ACOG guidelines that favor NPH or insulin detemir when basal insulin is needed, based on the existing safety record. If you are diagnosed with GDM, your provider is unlikely to prescribe Tresiba.

Lactation

Insulin does not transfer meaningfully into breast milk in biologically active amounts, and even if trace amounts were present, oral insulin is degraded in the infant's gastrointestinal tract. The FDA label states that it is unknown whether insulin degludec is present in human milk, but the physiological expectation is that transfer is minimal and systemic infant exposure is negligible. Breastfeeding women may experience lower insulin requirements postpartum, partly because lactation itself is insulin-sensitizing. Monitor fasting glucose closely in the first weeks postpartum and expect to reduce basal dose.

Contraception Note

Tresiba is not a teratogen in the way that some diabetes medications are (for example, metformin is generally continued, while ACE inhibitors used for diabetic nephropathy must be stopped). However, because uncontrolled diabetes at conception increases the risk of neural tube defects and cardiac malformations, women of reproductive age using insulin for type 1 or type 2 diabetes should discuss contraception planning with their provider. Achieving a hemoglobin A1c below 6.5% before conception is the ACOG-recommended target to minimize fetal risk, regardless of which insulin is used.

Who Is a Good Candidate for Tresiba and Who Is Not

Women Who May Benefit Most

Women with insulin-treated type 1 or type 2 diabetes who have experienced nocturnal hypoglycemia on insulin glargine U-100 or insulin detemir are the most clearly supported candidates based on the DEVOTE hypoglycemia data. The lower hypoglycemia rate, particularly overnight, is the strongest clinical differentiator.

Women with irregular schedules, including shift workers, those with newborns, and perimenopausal women with disrupted sleep, may find the dosing flexibility (minimum 8-hour spacing, any time of day) more manageable than a fixed-time insulin.

Women with type 2 diabetes who need high total daily doses may benefit from Tresiba U-200, which delivers 200 units per milliliter and allows larger doses in smaller injection volumes.

Women Who Should Use a Different Insulin

Pregnant women should generally switch to NPH or insulin detemir, which carry more human safety data. Women with a history of severe, unpredictable hypoglycemia who are not on CGM require careful evaluation before starting any long-acting basal analog with a 25-hour half-life, because the duration of hypoglycemia correction may also be prolonged.

Women whose insurance does not cover Tresiba face a real access barrier. The list price is substantially higher than NPH, and biosimilar basal insulin options (such as insulin glargine biosimilars) may be more affordable with equivalent glycemic outcomes for many patients.

What the Tresiba Label Actually Says: Key Sections Summarized

The FDA-approved Tresiba label covers several points that women often ask about.

Approved Indications

Tresiba is approved to improve glycemic control in adults with diabetes mellitus, both type 1 and type 2. It is not approved for diabetic ketoacidosis.

Starting Doses

For insulin-naive type 2 diabetes, the label recommends starting at 10 units once daily. For patients converting from another basal insulin, the label advises a unit-to-unit conversion from insulin glargine or insulin detemir, with the understanding that individual titration will follow.

Warnings and Contraindications

The label lists hypoglycemia as the most common adverse reaction and warns specifically about the risk of medication errors between Tresiba U-100 and Tresiba U-200, which are not interchangeable unit-for-unit using the same syringe. The FlexTouch pen is pre-set for the correct concentration; using a standard insulin syringe with Tresiba U-200 vials would result in a 200% overdose.

Tresiba is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any excipients.

Drug Interactions Relevant to Women

Several drug classes relevant to women's health can affect insulin requirements. Oral contraceptives and hormone therapy containing estrogen or progestins can raise blood glucose and may require basal dose increases. Thyroid hormones, when dose-adjusted, alter insulin sensitivity and may require basal dose changes in women being treated for hypothyroidism. Beta-blockers can mask tachycardia as a hypoglycemia symptom, which is especially relevant for women on metoprolol or atenolol for cardiovascular or migraine indications.

FDA Sentinel and Ongoing Post-Market Safety Surveillance

The FDA uses its Sentinel System to monitor real-world safety signals for approved drugs, including Tresiba. Sentinel draws on claims data from tens of millions of insured Americans. For insulin degludec, post-market surveillance has focused on hypoglycemia-related emergency department visits and hospitalizations, medication errors related to concentration confusion between U-100 and U-200 formulations, and cardiovascular events.

No new safety signals have prompted label changes since approval as of the date of this article. The concentration-confusion risk has led to FDA safety communications and label updates emphasizing that U-100 and U-200 pens are not interchangeable even though both deliver the prescribed number of units from the pen device. The distinction matters because Tresiba U-200 is not available as a vial in the United States, precisely to reduce the overdose risk that would arise from drawing U-200 into a standard syringe.